We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
VistaGen Therapeutics Provides Investor Update on Corporate Activities and Upcoming Initiatives
News

VistaGen Therapeutics Provides Investor Update on Corporate Activities and Upcoming Initiatives

VistaGen Therapeutics Provides Investor Update on Corporate Activities and Upcoming Initiatives
News

VistaGen Therapeutics Provides Investor Update on Corporate Activities and Upcoming Initiatives

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "VistaGen Therapeutics Provides Investor Update on Corporate Activities and Upcoming Initiatives"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

VistaGen Therapeutics, Inc., provides a comprehensive update on the Company's strategic plan to develop and commercialize its technology platform and lead small molecule CNS drug candidate.

Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "Since inception thirteen years ago, we have obtained and carefully employed more than $41 million from various strategic collaborations, investments and grant awards. Our Company has been tremendously resourceful, advancing a cutting-edge technology discovered during the first era of stem cell research to create a portfolio of proprietary technologies with incredible therapeutic and commercial potential in multiple applications."

"We are currently focused on three large market opportunities to leverage our versatile stem technology platform and CNS drug development capabilities," he continued. "We are using our stem cell technology platform, Human Clinical Trials in a Test Tube™, for both drug rescue and cell therapy. Our CNS drug development efforts are currently focused on clinical studies of AV-101 for neuropathic pain."

Human Clinical Trials in a Test Tube™ and CardioSafe 3D™
VistaGen's Human Clinical Trials in a Test Tube™ platform is based on a combination of proprietary and exclusively licensed pluripotent stem cell technologies, including technologies developed over the last 20 years by Canadian scientist Dr. Gordon Keller, and Dr. Ralph Snodgrass, VistaGen's founder, President and Chief Scientific Officer.

Dr. Keller is currently the Director of the University Health Network's McEwen Centre for Regenerative Medicine in Toronto. His research is focused on understanding and controlling stem cell differentiation and production of multiple types of mature, functional, human cells from pluripotent stem cells, including heart cells and liver cells that can be used in VistaGen's biological assay systems for drug rescue.

Dr. Snodgrass has nearly 20 years experience in both academia and industry in the development and application of stem cell differentiation systems for drug discovery and development.

VistaGen has leveraged its Human Clinical Trials in a Test Tube™ platform to produce mature human heart cells from pluripotent stem cells. Using mature, functional human heart cells, VistaGen has developed CardioSafe 3D™, its initial three-dimensional, stem cell technology-based bioassay system.

VistaGen believes CardioSafe 3D™ is capable of predicting many of the in vivo cardiac effects, both toxic and non-toxic, of small molecule drug candidates before they are tested in humans.

Drug Rescue
Drug rescue combines human pluripotent stem cell technology with modern medicinal chemistry to generate new chemical variants of once promising drug candidates that have been discontinued during preclinical development by pharmaceutical companies due to heart or liver safety concerns despite positive efficacy data demonstrating potential therapeutic and commercial benefits.

VistaGen's drug rescue model is designed to leverage both the pharmaceutical company's substantial prior investment in preclinical development of the drug candidate put on the shelf and the predictive toxicology and drug development capabilities of its Human Clinical Trials in a Test Tube™ platform.

VistaGen's goal is to use CardioSafe 3D™ to generate and monetize a pipeline of small molecule drug rescue variants through drug rescue collaborations focused on heart toxicity.

VistaGen plans to expand the drug rescue capabilities of its Human Clinical Trials in a Test Tube™ platform by developing a second bioassay system, LiverSafe 3D™, using mature human liver cells produced from pluripotent stem cells to predict liver toxicity and drug metabolism.

Cell Therapy
In parallel with its drug rescue activities and in collaboration with Dr. Gordon Keller in Toronto, VistaGen is preparing to initiate pilot preclinical cell therapy programs involving the proprietary stem cell differentiation and cell production capabilities of its Human Clinical Trials in a Test Tube™ platform.

The Company's cell therapy programs are scheduled to begin by year end and are currently focused on high value heart, liver and cartilage repair markets, as well as hematopoietic stem cells for autologous blood cell transplantation.

AV-101 for CNS Conditions and Diseases
VistaGen plans to begin its second Phase 1b clinical study of AV-101 for treatment of neuropathic pain before the end of 2011. The Company plans to include a model of neuropathic pain as a proxy for efficacy in this study. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone.

VistaGen plans to complete Phase 1 development of AV-101 in the fourth quarter of 2012. Based upon Phase 1 clinical data to date, the Company anticipates advancing AV-101 into Phase 2 development for neuropathic pain by the end of 2012.

VistaGen is also exploring additional opportunities to leverage its current Phase 1 clinical program to enable Phase 2 clinical studies of AV-101 for epilepsy and Parkinson's disease. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

Advertisement